Strategies for VTE Prophylaxis in Cancer for Inpatient, Outpatient Settings
Recommendations for venous thromboembolism prophylaxis in patients with cancer were discussed in an oral session at JADPRO Live 2022.
Recommendations for venous thromboembolism prophylaxis in patients with cancer were discussed in an oral session at JADPRO Live 2022.
Researchers sought to determine whether the Khorana score would be able to risk-stratify patients according to the 6-month risk of incident VTE.
Researchers sought to explore potential links between blood type, risk of venous thromboembolism, and cancer type in patients with cancer.
A new study suggests apixaban may be a potential treatment for cancer-associated venous thromboembolism, with possible variation in outcomes by cancer site.
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.